---
title: Synthetic CBD as a Therapy for COVID-19
nct_id: NCT04686539
overall_status: UNKNOWN
phase: PHASE1
sponsor: Sheba Medical Center
study_type: INTERVENTIONAL
primary_condition: Covid19
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04686539.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04686539"
ct_last_update_post_date: 2021-09-28
last_seen_at: "2026-05-12T07:13:57.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Synthetic CBD as a Therapy for COVID-19

**Official Title:** Synthetic CBD Oil Droplets as a Therapy for Mild to Moderate SARS-CoV-2 Infection. Assesment of Efficacy and Safety.

**NCT ID:** [NCT04686539](https://clinicaltrials.gov/study/NCT04686539)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Sheba Medical Center
- **Conditions:** Covid19, CBD
- **Start Date:** 2021-01-20
- **Completion Date:** 2022-01
- **CT.gov Last Update:** 2021-09-28

## Brief Summary

The study aim to test proof of concept of CBD treatment for efficacy and safety in patients suffering with mild COVID-19 infection. The CBD will be delivered via oil droplets not containing THC, compared to placebo.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* COVID 19 patients
* 18 Years and older

Exclusion Criteria:

* Respiratory failure requiring mechanical ventilation
* Intensive care unit admission
* Neutrophile con. \< 1000 cells/mm3
* Lymphocyte con \< 500 cells/mm3
* Liver enzymes 5 times higher then the norm
* QT interval longer then 500 ms.
* Pregnancy
* Hemodialysis renal replacement therapy
* Active or prior psychotic event
```

## Arms

- **Recipients of CBD oil** (EXPERIMENTAL) — Patients receiving Cannabidiol oil drops, administered sublingual, 3 times a day, while hospitalized. Dosing and administration frequency would be assessed bi-daily by the medical staff.
- **Recipients of Placebo** (PLACEBO_COMPARATOR) — Patients receiving placebo oil, administered sublingual, 3 times a day, while hospitalized.

## Interventions

- **CBD** (DRUG) — CBD oil not containing THC, to be administered sub-lingual.
- **Placebo** (DRUG) — Placebo Oil

## Primary Outcomes

- **Clinical deterioration** _(time frame: 14 days)_ — Patients chance of clinical deterioration of COVID19 disease as defined by percentage of patients requiring oxygen therapy during their hospitalization.

## Secondary Outcomes

- **Changes in NEWS scale** _(time frame: 14 days)_
- **Supportive care therapies** _(time frame: 14 days)_
- **SARS-COV2 presence** _(time frame: 10 days, 14 days)_
- **Hospitalization Days** _(time frame: 14 days)_
- **Cytokine Levels** _(time frame: Day 3, day 7, discharge day (which is on average the 10th day of hospitalization).)_
- **Hamilton Anxiety Score** _(time frame: 14 days)_

## Locations (1)

- Sheba Medical Center, Tel Hashomer, Ramat Gan, Tel Aviv, Israel — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.sheba medical center, tel hashomer|ramat gan|tel aviv|israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04686539.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04686539*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*